Glaucoma and THC Treatment

Glaucoma is the second leading cause of blindness in human beings. It is a very common disease that strikes a significant number of people as they age. It is referred to as the silent thief of eyesight, because it can be a progressive and very gradual disease. Often people developing glaucoma will not feel pain.

The disease might not cause drastic eyesight damage until it is in its advanced phases. The first thing to be affected in many cases is peripheral vision, which people might not notice deteriorating. The problem with waiting until the advanced stages of Glaucoma is by then it is difficult to treat.

For someone who is at risk of glaucoma, the only safety is in routine eye examination. Pressure in the eyeball is one sign, although there cases where glaucoma does not involve increased pressure in the inside fluid. Optometrists can spot the early signs of damage by testing peripheral vision. Bloodshot eyes are another sign of discomfort to the organ.



Of equal significance is how to treat glaucoma. Many medicines have been advised, including those that lower overall blood pressure. Pain relievers eliminate discomfort but do not treat the condition. Some doctors are looking into the drug THC for a possible new cure.

THC is the active ingredient in cannabis, which is still marred to some degree by being a controlled substance. Medicine derived from plants can be powerful when properly applied, and THC shows potential to alleviate the symptoms of glaucoma. Testing in the 1970s proved that THC can lower pressure in the eyes, thereby reducing glaucoma damage.

The drug itself is not harmful to people except in very rare cases where it can increase anxiety. It is not necessary to smoke cannabis, and when taken orally is a very safe medicine. While some stigma towards cannabis still exists, the many medicinal properties without a toxicity suggests an ideal option for other drugs.

Cannabis treatment research should be funded simply because it is less risky than surgery. It could be the cheaper alternative for many glaucoma sufferers, who could have trouble affording more expensive treatments.

Clinical Trials, Studies and Publications: